Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval

Drug Will Be Known As Leqvio

Timing means full EU approval could coincide with US FDA authorization later this year.

Amsterdam, March 2020. Entrance of the office from the European Medicines Agency (EMA) in Amsterdam
The European Medicine Agency in Amsterdam.

Novartis could gain European Union approval for its novel cholesterol treatment inclisiran by the end of the year, following a nod from a key regulatory committee.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended marketing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip